Skip to main content
. 2022 Aug 10;22(11):1565–1576. doi: 10.1016/S1473-3099(22)00420-0

Figure 3.

Figure 3

Serum IgG titres and neutralising antibody activity for the ancestral SARS-CoV-2 strain by study day (log scale)

(A) Geometric mean anti-spike IgG ELISA unit responses to recombinant SARS-CoV-2 protein antigens at baseline (day 0), 3 weeks after first vaccination (day 21), 2 weeks after second vaccination (day 35), 12 weeks after second vaccination (day 105), on the day of third vaccination (day 189), and 4 weeks after third vaccination (day 217). Data are from a qualified ancestral strain IgG assay. (B) Microneutralisation antibodies showing response at an inhibitory concentration of more than 50% to recombinant SARS-CoV-2 protein antigens at baseline (day 0), 3 weeks after first vaccination (day 21), 2 weeks after second vaccination (day 35), 12 weeks after second vaccination (day 105), on the day of third vaccination (day 189), and 4 weeks after third vaccination (day 217). Values represent the GMTs and error bars represent the 95% CIs. Data are from a qualified ancestral strain microneutralisation assay. Data are shown overall and by age group in the NVX-CoV2373–NVX-CoV2373 group, and overall in the group that received three doses of placebo. GMT=geometric mean titre.